OCX Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 23:00):

Stats
Dzisiejszy wolumen	15 316.00
Średni wolumen	58 617.00
Kapitalizacja rynkowa	22.01M
EPS	$0 ( 2024-03-29 )
Następna data zysków	( $-0.820 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.790
ATR14	$0.0410 (1.52%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-11	Broadwood Partners, L.p.	Buy	2 420 000	Common Stock, no par value
2024-04-11	Broadwood Partners, L.p.	Buy	0	Common Stock, no par value
2024-04-15	Broadwood Partners, L.p.	Sell	0	Series A Convertible Preferred Stock
2024-04-11	Riggs Josh	Buy	3 390	Common Stock, no par value
2024-04-11	Arno Andrew	Buy	33 898	Common Stock, no par value

INSIDER POWER
37.39
Last 97 transactions
Buy: 36 875 696 \| Sell: 16 930 326

OncoCyte Corp Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

OncoCyte Corp Korelacja - Waluta/Towar

-0.06
( neutral )

-0.40
( neutral )

0.00
( neutral )

-0.39
( neutral )

0.73
( moderate )

0.57
( weak )

OncoCyte Corp Finanse

Annual	2023
Przychody:	$1.50M
Zysk brutto:	$501 000 (33.33 %)
EPS:	$-3.63

FY	2023
Przychody:	$1.50M
Zysk brutto:	$501 000 (33.33 %)
EPS:	$-3.63

FY	2022
Przychody:	$958 000
Zysk brutto:	$-18 000.00 (-1.88 %)
EPS:	$-13.26

FY	2021
Przychody:	$7.73M
Zysk brutto:	$188 000 (2.43 %)
EPS:	$-0.720

Financial Reports:

No articles found.

OncoCyte Corp

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

Aktualne aktualizacje dla OncoCyte Corp [OCX]

Upcoming Earnings Alert